Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Therapeutic Drug Monitoring

Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation

View Full Paper
Ask AI
Bookmark
Share

Authors

AVAnna Vidal‐AlabróPFPere FontovaZAZeyar Mohammed Ali

Discussion

Loading...

Member takes

Overview

Enzyme polymorphisms affect tacrolimus exposure in kidney transplant patients, suggesting tailored dosing may be crucial.

Key Points

  • Patients with CYP3A5*1 genotypes showed altered pharmacokinetic responses to tacrolimus conversion.
  • Higher AUC 0–24h values were observed in CYP3A5*1 expressers after transitioning to prolonged-release tacrolimus.
  • Observational analysis involved 19 kidney transplant recipients undergoing genotyping and dosing adjustments post-conversion.
  • Results point to the significance of understanding genetic factors for effective immunosuppressant therapy.

Cite This Study

Vidal‐Alabró et al. (2025) studied this question.

synapsesocial.com/papers/69401f0f2d562116f28fa19ehttps://doi.org/10.1097/ftd.0000000000001411
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study2025
  2. 2Optimizing Dose Conversion From IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling Study2025
  3. 3Cohort Study to Determine the Impact of <i>CYP3A5</i> Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients2026
  4. 4Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression2025 · 2 citations
  5. 5Extended-Release Tacrolimus Versus LifeCycle Pharma Tacrolimus in Kidney Transplant Recipients: A Switch Study2026